Aim: This systematic review evaluates the diagnostic accuracy of preschool vision screening tests for the detection of amblyopia and its risk factors.
Methods: The literature searches were conducted in nine bibliographic databases. No limitation to a specific study design, year of publication or language was applied. Studies were included if they compared a vision screening test with a reference test (gold standard) in children from the general population. In addition, the studies had to provide sufficient data to calculate diagnostic accuracy (sensitivity and specificity). Full-text articles were assessed for studies that satisfied the inclusion criteria using the "Quality of Diagnostic Accuracy Studies (QUADAS)" checklist.
Results: Two studies with a longitudinal design and 25 cross-sectional studies met the inclusion criteria. One of the longitudinal studies compared a screening programme in children between 1 and 2 years of age with a re-examination at the age of 8. The sensitivity for the screening programme was 86% (range: 64-97%) and the specificity 99% (range: 98-99%). The second longitudinal study compared screening examinations at 8, 12, 18, 25 and 31 months, with a re-examination at the age of 37 months. In this study, the sensitivity of the screening examination increased with age, while the specificity remained unchanged. The cross-sectional studies evaluated different screening settings, visual acuity tests, auto- or photorefractors and stereo tests. A large variety of reference tests, differing criteria for defining amblyopia and its risk factors and methodological limitations of the studies prevented a valid data interpretation.
Conclusion: Diagnostic test accuracy of preschool vision screening tests can only be sufficiently investigated after establishing age-related values defining amblyopia, refractive errors and binocular disorders. To address these questions, we recommend a controlled longitudinal study design.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00417-009-1150-2 | DOI Listing |
Alzheimers Dement
December 2024
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Numerous drugs (including disease-modifying therapies, cognitive enhancers and neuropsychiatric treatments) are being developed for Alzheimer's and related dementias (ADRD). Emerging neuroimaging modalities, and genetic and other biomarkers potentially enhance diagnostic and prognostic accuracy. These advances need to be assessed in real-world studies (RWS).
View Article and Find Full Text PDFUp to date, there are no precise reports of the prevalence of dementia with Lewy bodies (DLB) in Latin America. This can be explained by the lack of research studies and general little awareness about the disease. Notably, collaborative clinical studies are lacking, and DLB patients remain underrepresented despite their significant morbidity.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
National University, Muscat, Muscat, Oman.
Background: This study explores Alzheimer's prediction through brain MRI images, utilizing Convolutional Neural Networks (CNNs) and Lime interpretability. Based on an extensive ADNI MRI dataset, we demonstrate promising results in predicting Alzheimer's disease. Local Interpretable Model Agnostic Explanations (LIME) shed light on decision-making processes, enhancing transparency.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
The Education University of Hong Kong, Tai Po, New Territories, Hong Kong.
Background: Lexical retrieval therapy (LRT) has been proven to be an effective speech therapy for individuals with semantic variant primary progressive aphasia (svPPA) and semantic cue plays an important ingredient in LRT. In recent findings, differential performance in using and choosing noun-classifiers amongst Chinese individuals with the three subtypes of PPA were observed. The current study aims to explore the treatment effect of employing noun-classifier as a semantic cue of LRT for Cantonese-speaking svPPA.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Infovital, Envigado, Colombia.
Background: Currently, the diagnosis of Alzheimer's disease dementia (ADD) is determined based on clinical criteria, as well as specific imaging and cerebrospinal fluid (CSF) biomarker profiles. However, healthcare professionals face a variety of challenges that hinder their application, such as the interpretation and integration or large amounts of data derived from neuropsychological assessment, the importance attributed to each source of information and the impact of unknown variables, among others. Therefore, this research focuses on the development of a computerized diagnostic tool based on Artificial Intelligence (AI), to strengthen the capacity of healthcare professionals in the identification and diagnosis of ADD.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!